Cargando…

Key biomarkers and latent pathways of dysferlinopathy: Bioinformatics analysis and in vivo validation

BACKGROUND: Dysferlinopathy refers to a group of muscle diseases with progressive muscle weakness and atrophy caused by pathogenic mutations of the DYSF gene. The pathogenesis remains unknown, and currently no specific treatment is available to alter the disease progression. This research aims to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yan, Li, Ying-hui, Chen, Kai, Zhu, Chun-yan, Bai, Jia-ying, Xiao, Feng, Tan, Song, Zeng, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530905/
https://www.ncbi.nlm.nih.gov/pubmed/36203997
http://dx.doi.org/10.3389/fneur.2022.998251
_version_ 1784801786110935040
author Xie, Yan
Li, Ying-hui
Chen, Kai
Zhu, Chun-yan
Bai, Jia-ying
Xiao, Feng
Tan, Song
Zeng, Li
author_facet Xie, Yan
Li, Ying-hui
Chen, Kai
Zhu, Chun-yan
Bai, Jia-ying
Xiao, Feng
Tan, Song
Zeng, Li
author_sort Xie, Yan
collection PubMed
description BACKGROUND: Dysferlinopathy refers to a group of muscle diseases with progressive muscle weakness and atrophy caused by pathogenic mutations of the DYSF gene. The pathogenesis remains unknown, and currently no specific treatment is available to alter the disease progression. This research aims to investigate important biomarkers and their latent biological pathways participating in dysferlinopathy and reveal the association with immune cell infiltration. METHODS: GSE3307 and GSE109178 were obtained from the Gene Expression Omnibus (GEO) database. Based on weighted gene co-expression network analysis (WGCNA) and differential expression analysis, coupled with least absolute shrinkage and selection operator (LASSO), the key genes for dysferlinopathy were identified. Functional enrichment analysis Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were applied to disclose the hidden biological pathways. Following that, the key genes were approved for diagnostic accuracy of dysferlinopathy based on another dataset GSE109178, and quantitative real-time polymerase chain reaction (qRT-PCR) were executed to confirm their expression. Furthermore, the 28 immune cell abundance patterns in dysferlinopathy were determined with single-sample GSEA (ssGSEA). RESULTS: 1,579 differentially expressed genes (DEGs) were screened out. Based on WGCNA, three co-expression modules were obtained, with the MEskyblue module most strongly correlated with dysferlinopathy. 44 intersecting genes were recognized from the DEGs and the MEskyblue module. The six key genes MVP, GRN, ERP29, RNF128, NFYB and KPNA3 were discovered through LASSO analysis and experimentally verified later. In a receiver operating characteristic analysis (ROC) curve, the six hub genes were shown to be highly valuable for diagnostic purposes. Furthermore, functional enrichment analysis highlighted that these genes were enriched mainly along the ubiquitin-proteasome pathway (UPP). Ultimately, ssGSEA showed a significant immune-cell infiltrative microenvironment in dysferlinopathy patients, especially T cell, macrophage, and activated dendritic cell (DC). CONCLUSION: Six key genes are identified in dysferlinopathy with a bioinformatic approach used for the first time. The key genes are believed to be involved in protein degradation pathways and the activation of muscular inflammation. And several immune cells, such as T cell, macrophage and DC, are considered to be implicated in the progression of dysferlinopathy.
format Online
Article
Text
id pubmed-9530905
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95309052022-10-05 Key biomarkers and latent pathways of dysferlinopathy: Bioinformatics analysis and in vivo validation Xie, Yan Li, Ying-hui Chen, Kai Zhu, Chun-yan Bai, Jia-ying Xiao, Feng Tan, Song Zeng, Li Front Neurol Neurology BACKGROUND: Dysferlinopathy refers to a group of muscle diseases with progressive muscle weakness and atrophy caused by pathogenic mutations of the DYSF gene. The pathogenesis remains unknown, and currently no specific treatment is available to alter the disease progression. This research aims to investigate important biomarkers and their latent biological pathways participating in dysferlinopathy and reveal the association with immune cell infiltration. METHODS: GSE3307 and GSE109178 were obtained from the Gene Expression Omnibus (GEO) database. Based on weighted gene co-expression network analysis (WGCNA) and differential expression analysis, coupled with least absolute shrinkage and selection operator (LASSO), the key genes for dysferlinopathy were identified. Functional enrichment analysis Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) were applied to disclose the hidden biological pathways. Following that, the key genes were approved for diagnostic accuracy of dysferlinopathy based on another dataset GSE109178, and quantitative real-time polymerase chain reaction (qRT-PCR) were executed to confirm their expression. Furthermore, the 28 immune cell abundance patterns in dysferlinopathy were determined with single-sample GSEA (ssGSEA). RESULTS: 1,579 differentially expressed genes (DEGs) were screened out. Based on WGCNA, three co-expression modules were obtained, with the MEskyblue module most strongly correlated with dysferlinopathy. 44 intersecting genes were recognized from the DEGs and the MEskyblue module. The six key genes MVP, GRN, ERP29, RNF128, NFYB and KPNA3 were discovered through LASSO analysis and experimentally verified later. In a receiver operating characteristic analysis (ROC) curve, the six hub genes were shown to be highly valuable for diagnostic purposes. Furthermore, functional enrichment analysis highlighted that these genes were enriched mainly along the ubiquitin-proteasome pathway (UPP). Ultimately, ssGSEA showed a significant immune-cell infiltrative microenvironment in dysferlinopathy patients, especially T cell, macrophage, and activated dendritic cell (DC). CONCLUSION: Six key genes are identified in dysferlinopathy with a bioinformatic approach used for the first time. The key genes are believed to be involved in protein degradation pathways and the activation of muscular inflammation. And several immune cells, such as T cell, macrophage and DC, are considered to be implicated in the progression of dysferlinopathy. Frontiers Media S.A. 2022-09-20 /pmc/articles/PMC9530905/ /pubmed/36203997 http://dx.doi.org/10.3389/fneur.2022.998251 Text en Copyright © 2022 Xie, Li, Chen, Zhu, Bai, Xiao, Tan and Zeng. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Xie, Yan
Li, Ying-hui
Chen, Kai
Zhu, Chun-yan
Bai, Jia-ying
Xiao, Feng
Tan, Song
Zeng, Li
Key biomarkers and latent pathways of dysferlinopathy: Bioinformatics analysis and in vivo validation
title Key biomarkers and latent pathways of dysferlinopathy: Bioinformatics analysis and in vivo validation
title_full Key biomarkers and latent pathways of dysferlinopathy: Bioinformatics analysis and in vivo validation
title_fullStr Key biomarkers and latent pathways of dysferlinopathy: Bioinformatics analysis and in vivo validation
title_full_unstemmed Key biomarkers and latent pathways of dysferlinopathy: Bioinformatics analysis and in vivo validation
title_short Key biomarkers and latent pathways of dysferlinopathy: Bioinformatics analysis and in vivo validation
title_sort key biomarkers and latent pathways of dysferlinopathy: bioinformatics analysis and in vivo validation
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9530905/
https://www.ncbi.nlm.nih.gov/pubmed/36203997
http://dx.doi.org/10.3389/fneur.2022.998251
work_keys_str_mv AT xieyan keybiomarkersandlatentpathwaysofdysferlinopathybioinformaticsanalysisandinvivovalidation
AT liyinghui keybiomarkersandlatentpathwaysofdysferlinopathybioinformaticsanalysisandinvivovalidation
AT chenkai keybiomarkersandlatentpathwaysofdysferlinopathybioinformaticsanalysisandinvivovalidation
AT zhuchunyan keybiomarkersandlatentpathwaysofdysferlinopathybioinformaticsanalysisandinvivovalidation
AT baijiaying keybiomarkersandlatentpathwaysofdysferlinopathybioinformaticsanalysisandinvivovalidation
AT xiaofeng keybiomarkersandlatentpathwaysofdysferlinopathybioinformaticsanalysisandinvivovalidation
AT tansong keybiomarkersandlatentpathwaysofdysferlinopathybioinformaticsanalysisandinvivovalidation
AT zengli keybiomarkersandlatentpathwaysofdysferlinopathybioinformaticsanalysisandinvivovalidation